If you are wondering whether Revolution Medicines at around US$107.39 still offers value after its recent run, you are not alone.
The stock has seen large moves recently, with returns of 35.9% over the past week, 37.9% over the past month, 35.9% year to date, 157.0% over the past year and 256.9% over the past three years.
These price moves have arrived alongside increased investor attention on the company, including ongoing coverage of its targeted oncology pipeline and its position in the RAS-focused therapies space. This context helps frame whether the recent share price action reflects changing expectations around its prospects or simply shifting risk appetite in the biotech sector.
On our checks, Revolution Medicines currently has…
